Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated with pulsed field ablation (PFA) therapy using the Volt PFA System for atrial ...

Atrial fibrillation remains a common and challenging cardiac arrhythmia, particularly in hypertensive patients, who face a ...

Medtronic (MDT) announced positive clinical outcomes from two studies in atrial fibrillation, AFib, patients treated with the Affera family of ...

Abbott (ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Abbott has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volttm PFA System ...

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt PFA SystemThe 12-month results of the ...

Medtronic plc , a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Afferatm family of ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

Abbott (NYSE: ABT) today announced new study data demonstrating the safety and efficacy of its Volt pulsed field ablation ...